RA21 Corporate Pilot

RA21 Corporate Pilot

The RA21 Corporate Pilot seeks to validate the use of SAML-based federated authentication technologies to provide seamless access to scholarly resources for authorized users at P-D-R companies.  The pilot seeks to demonstrate how the use of (Pharma-Documentation-Ring) P-D-R companies’ corporate login credentials can be leveraged to provide the same type of seamless access to scholarly resources that today’s IP address authentication provides.

The pilot includes five participants from P-D-R companies, and four STM publishers. The corporate pilot will run from 1st January 2017 until 30th June 2017.

Objectives

The pilot project will focus on access to publisher resources by authorised users using desktop or mobile devices outside the corporate network.

The specific goals of the corporate pilot are as follows:

  1. To improve the current user experience at the publisher’s site for redirecting the user site back to their company’s identity server for authentication. The user experience should be consistent across multiple STM publisher’s sites; regardless of the user’s location and device used.
  2. To explore the use of SAML attributes to meet usage statistics needs.
  3. Explore the ability to share user logins across publishers.  (This 3rd goal is considered of secondary importance).

The pilot projects will consider both the privacy (e.g., GDPR 2018) and corporate compliance aspects of a new authentication solution.

Participating Organizations

  • AbbVie
  • BASF
  • CCC
  • Elsevier
  • GSK
  • Novartis
  • Roche
  • SpringerNature
  • Wiley